William Blair Reports Initiation of Gilead Sciences (GILD); Riverhead Capital Management Decreased Omnicom Group (OMC) Position



August 31, 2017 – By Winifred Garcia

Riverhead Capital Management Llc decreased Omnicom Group Inc (OMC) stake by 8.75% reported in 2016Q4 SEC filing. Riverhead Capital Management Llc sold 12,300 shares as Omnicom Group Inc (OMC)’s stock declined 2.32%. The Riverhead Capital Management Llc holds 128,201 shares with $10.91M value, down from 140,501 last quarter. Omnicom Group Inc now has $16.64B valuation. The stock declined 0.25% or $0.18 reaching $72.13 per share. About 288,774 shares traded. Omnicom Group Inc. (NYSE:OMC) has risen 1.15% since August 31, 2016 and is uptrending. It has underperformed by 15.55% the S&P500.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 19 have Buy rating, 0 Sell and 11 Hold. Therefore 63% are positive. Gilead Sciences has $137 highest and $7200 lowest target. $99.82’s average target is 19.16% above currents $83.77 stock price. Gilead Sciences had 84 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Hold” rating by BMO Capital Markets given on Friday, July 21. The stock has “Buy” rating by Jefferies on Monday, June 12. The company was initiated on Friday, December 18 by Atlantic Securities. RBC Capital Markets maintained Gilead Sciences, Inc. (NASDAQ:GILD) rating on Wednesday, November 2. RBC Capital Markets has “Outperform” rating and $90 target. Mizuho initiated it with “Buy” rating and $88 target in Tuesday, November 8 report. On Monday, September 12 the stock rating was initiated by Berenberg with “Buy”. As per Tuesday, September 6, the company rating was upgraded by Jefferies. The rating was maintained by Piper Jaffray on Wednesday, February 3 with “Overweight”. The rating was maintained by Cowen & Co with “Buy” on Tuesday, July 25. The firm earned “Equal-Weight” rating on Friday, October 2 by Morgan Stanley.

Investors sentiment increased to 0.93 in 2016 Q4. Its up 0.02, from 0.91 in 2016Q3. It improved, as 106 investors sold Gilead Sciences, Inc. shares while 656 reduced holdings. 111 funds opened positions while 421 raised stakes. 950.84 million shares or 0.69% more from 944.29 million shares in 2016Q3 were reported. Beacon Trust stated it has 34,146 shares. Waverton Invest Mngmt Limited reported 1.02M shares. Royal Fincl Bank Of Canada invested 0.15% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Condor Cap Management accumulated 11,202 shares. Rhenman And Prtn Asset Mngmt stated it has 259,894 shares or 3.57% of all its holdings. Artemis Inv Mngmt Limited Liability Partnership invested in 0.01% or 5,204 shares. Apriem Advsr stated it has 5,070 shares or 0.11% of all its holdings. Highbridge Capital Mngmt Lc invested in 422,835 shares or 0.54% of the stock. Ariel Capital Llc has invested 0.32% in Gilead Sciences, Inc. (NASDAQ:GILD). Exchange Capital holds 0.01% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 240 shares. Employees Retirement Association Of Colorado has 0.43% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Glg Prtn Lp, United Kingdom-based fund reported 12,002 shares. Violich Capital Management Inc has 1.71% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Loomis Sayles And Com Ltd Partnership has 0% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 1,290 shares. Bkd Wealth Advsr Limited Company owns 2,870 shares.

Gilead Sciences, Inc. is a research biopharmaceutical firm that discovers, develops and commercializes medicines in areas of unmet medical need. The company has market cap of $109.40 billion. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome , liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. It has a 9.09 P/E ratio. The Company’s products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta.

Since March 1, 2017, it had 0 buys, and 7 insider sales for $16.39 million activity. 5,000 Gilead Sciences, Inc. (NASDAQ:GILD) shares with value of $325,114 were sold by Alton Gregg H. MARTIN JOHN C had sold 73,333 shares worth $4.78 million on Thursday, June 1. Cogan John Francis sold 9,943 shares worth $668,667.

About 8.03M shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since August 31, 2016 and is downtrending. It has underperformed by 38.50% the S&P500.

Riverhead Capital Management Llc increased Ingersoll (NYSE:IR) stake by 12,700 shares to 23,123 valued at $1.74 million in 2016Q4. It also upped Discovery Communications Inc (NASDAQ:DISCK) stake by 22,500 shares and now owns 29,700 shares. Copa Holdings Sa (NYSE:CPA) was raised too.

Since June 1, 2017, it had 0 insider buys, and 1 insider sale for $1.94 million activity. The insider CRAWFORD BRUCE sold 22,800 shares worth $1.94M.

Among 13 analysts covering Omnicom (NYSE:OMC), 3 have Buy rating, 0 Sell and 10 Hold. Therefore 23% are positive. Omnicom had 26 analyst reports since July 23, 2015 according to SRatingsIntel. The stock of Omnicom Group Inc. (NYSE:OMC) earned “Neutral” rating by Credit Suisse on Thursday, September 15. The stock of Omnicom Group Inc. (NYSE:OMC) has “Buy” rating given on Wednesday, April 12 by RBC Capital Markets. The firm has “Market Perform” rating by Telsey Advisory Group given on Wednesday, July 20. The stock of Omnicom Group Inc. (NYSE:OMC) has “Hold” rating given on Thursday, July 13 by BMO Capital Markets. Wells Fargo maintained Omnicom Group Inc. (NYSE:OMC) on Monday, July 17 with “Hold” rating. The company was maintained on Monday, August 14 by Jefferies. The stock has “Overweight” rating by JP Morgan on Monday, March 21. Jefferies maintained it with “Hold” rating and $8200 target in Monday, June 5 report. The firm has “Buy” rating given on Tuesday, August 22 by RBC Capital Markets. The firm earned “Sector Perform” rating on Friday, October 7 by RBC Capital Markets.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *

*

16 + 3 =